Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01727440 · ClinicalTrials.gov registry record
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 123
- Enrollment target
NCT01727440 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 123 participants.
The verdict
NCT01727440 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 123 participants
- Enrollment target
Study Summary
The goal of this study is to enroll 250 participants that have joined the MURDOCK Study Horizon 1.5 (Duke IRB Pro00011196) with a current or prior diagnosis of severe acne AND current or prior treatment with oral isotretinoin. All 250 participants will answer a 5-page questionnaire designed to collect information on the diagnosis of severe acne and response to oral isotretinoin treatment. The aim is to identify genetic predictors of severe acne vulgaris and the outcome of oral isotretinoin treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01727440
The ClinicalTrials.gov registry entry for NCT01727440 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01727440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01727440 about?
NCT01727440 is a clinical study titled "Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment". The goal of this study is to enroll 250 participants that have joined the MURDOCK Study Horizon 1.5 (Duke IRB Pro00011196) with a current or prior diagnosis of severe acne AND current or prior treatment with oral isotretinoin. All 250 participants will answer a 5-page questionnaire designed to colle...
What is the current status of trial NCT01727440?
This trial is currently completed. The enrollment target is 123 participants. The study started on 2011-09. Estimated completion is 2015-08.
Who is sponsoring clinical trial NCT01727440?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.